Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05394337 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
A Phase 1 study of Metastatic Malignancy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05394337 is a Phase 1 study of Metastatic Malignancy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05394337, a Phase 1 study of Metastatic Malignancy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tiragolumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05394337
The ClinicalTrials.gov registry entry for NCT05394337 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05394337 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05394337 about?
NCT05394337 is a clinical study titled "Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma". To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.
What is the current status of trial NCT05394337?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-02-23. Estimated completion is 2025-12-31.
What conditions does trial NCT05394337 study?
This clinical trial studies the following conditions: Metastatic Malignancy.
What interventions are being tested in trial NCT05394337?
The interventions under investigation include: Atezolizumab (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT05394337?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05394337 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.